ROLE OF COMPLEMENT ACTIVATION IN HYPERSENSITIVITY REACTIONS TO DOXIL AND HYNIC PEG LIPOSOMES: EXPERIMENTAL AND CLINICAL STUDIES

ABSTRACT Pegylated liposomal doxorubicin (Doxil) and 99mTc-HYNIC PEG liposomes (HPL) were reported earlier to cause hypersensitivity reactions (HSRs) in a substantial percentage of patients treated i.v. with these formulations. Here we report that (1) Doxil, HPL, pegylated phosphatidylethanolamine (PEG-PE)-containing empty liposomes matched with Doxil and HPL in size and lipid composition, and phosphatidylglycerol (PG)-containing negatively charged vesicles were potent C activators in human serum in vitro, whereas small neutral liposomes caused no C activation. (2) Doxil and other size-matched PEG-PE and/or PG-containing liposomes also caused massive cardiopulmonary distress with anaphylactoid shock in pigs via C activation, whereas equivalent neutral liposomes caused no hemodynamic changes. (3) A clinical study showed more frequent and greater C activation in patients displaying HSR than in non-reactive patients. These data suggest that liposome-induced HSRs in susceptible individuals may be due to C activation, which, in turn, is due to the presence of negatively charged PEG-PE in these vesicles.

[1]  H. Lutz,et al.  The Role of Complement Activation in Hypersensitivity to Pegylated Liposomal Doxorubicin (Doxil®) , 2000 .

[2]  Y. Barenholz,et al.  Clinical studies of liposome-encapsulated doxorubicin. , 1994, Acta oncologica.

[3]  A. Gabizon,et al.  Initial Clinical Evaluation of Pegylated-Liposomal Doxorubicin in Solid Tumors , 1998 .

[4]  W. Oyen,et al.  Tc-99m-PEG-Liposomes for the Evaluation of Colitis in Crohn's Disease , 2000, Journal of drug targeting.

[5]  A. Gabizon,et al.  Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  S. de Marie Liposomal and lipid-based formulations of amphotericin B. , 1996, Leukemia.

[7]  A. Gabizon Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.

[8]  J Szebeni,et al.  Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. , 1999, Circulation.

[9]  A. Giatromanolaki,et al.  Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  DifcoTM HycheckTM,et al.  The package insert. , 1969, JAMA.

[11]  F. Muggia,et al.  Liposomal encapsulated anthracyclines: new therapeutic horizons , 2001, Current oncology reports.

[12]  J. Codina,et al.  Sch-28080 depletes intracellular ATP selectively in mIMCD-3 cells. , 2000, American journal of physiology. Cell physiology.

[13]  Y. Barenholz,et al.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.

[14]  M. Bodó,et al.  Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. , 2000, American journal of physiology. Heart and circulatory physiology.

[15]  J. Szebeni,et al.  Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents. , 2001, Critical reviews in therapeutic drug carrier systems.

[16]  F M Muggia,et al.  Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.